Truist raised the firm’s price target on iRhythm (IRTC) to $95 from $80 and keeps a Buy rating on the shares. The company secured FDA approval for 1 of 2 anticipated ZioAT 510Ks, which is a “step in the right direction” for its management to start regaining credibility following numerous unanticipated FDA setbacks over the last 2 years, the analyst tells investors in a research note. iRhythm added it is also looking forward to hearing about the 2nd 510K “in the near-future”, and once both are in-hand, this should help the company remediate its current Warning Letter and keep a Zio MCT 510K submission on track for year-end 2024, the firm added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- iRhythm: FDA clears design updates previously made to Zio AT device
- iRhythm price target lowered to $80 from $117 at Truist
- Irhythm Technologies Outlines Growth and Market Leadership Strategy
- iRhythm initiated with a Neutral at Goldman Sachs